Weight & metabolic
Survodutide
Dual GLP-1/Glucagon Agonist
A dual-action peptide from Boehringer Ingelheim that combines GLP-1 and glucagon receptor activation. Takes a different approach than tirzepatide by using glucagon instead of GIP as its second target.
Also known as: BI 456906, BI456906
- Status
- Survodutide is in Phase 3 clinical trials and not approved.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- ~5-6 days (estimated)
- How it's taken
- Weekly subcutaneous injection
- Mechanism
- Incretin (GLP-1 / GIP / glucagon / amylin)
- Pathways
- GLP-1, Glucagon
How Survodutide works
Activates GLP-1 receptors to suppress appetite and improve insulin sensitivity, while simultaneously activating glucagon receptors to increase energy expenditure and promote fat breakdown in the liver. This combination is especially promising for fatty liver disease.
What research has looked at
- Strong weight loss results in trials
- Particularly effective at reducing liver fat
- Dual mechanism different from tirzepatide
- Promising results for metabolic liver disease (MASH)
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Nausea (most common)
- Vomiting
- Diarrhea
- Decreased appetite
- Injection site reactions
Sources
- Active clinical trials for survodutide · U.S. National Library of Medicine
- PubMed research on survodutide BI 456906 GLP-1 glucagon · NIH · National Library of Medicine
- DrugBank record for survodutide · DrugBank
Track Survodutide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Survodutide FAQ
What is Survodutide?
A dual-action peptide from Boehringer Ingelheim that combines GLP-1 and glucagon receptor activation. Takes a different approach than tirzepatide by using glucagon instead of GIP as its second target.
How does Survodutide work?
Activates GLP-1 receptors to suppress appetite and improve insulin sensitivity, while simultaneously activating glucagon receptors to increase energy expenditure and promote fat breakdown in the liver. This combination is especially promising for fatty liver disease.
Is Survodutide FDA approved?
No. Survodutide is in Phase 3 clinical trials and not approved. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of Survodutide?
Reported half-life: ~5-6 days (estimated).
How is Survodutide taken?
Weekly subcutaneous injection.
What side effects have been reported with Survodutide?
Reported in the sources: Nausea (most common); Vomiting; Diarrhea; Decreased appetite; Injection site reactions.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.